Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Darbepoetin alfa.

T Ibbotson1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|December 12, 2001
PubMed
Summary
This summary is machine-generated.

Darbepoetin alfa, a novel erythropoiesis-stimulating protein, effectively treats anemia in chronic kidney disease patients. It offers a longer half-life and similar efficacy to recombinant human erythropoietin (r-HuEPO) with less frequent dosing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention and early treatment of the long-term physical effects of COVID-19 in adults: design of a randomised controlled trial of resistance exercise-CISCO-21.

Trials·2022
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Laser-driven acceleration of electrons in a partially ionized plasma channel.

Physical review letters·2008
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Nephrology
  • Hematology

Background:

  • Anemia is a common complication in patients with chronic kidney disease (CKD).
  • Erythropoiesis-stimulating agents (ESAs) are crucial for managing anemia in CKD.
  • Darbepoetin alfa represents a novel ESA with potentially improved pharmacokinetic properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of darbepoetin alfa in treating anemia associated with CKD.
  • To compare darbepoetin alfa with recombinant human erythropoietin (r-HuEPO) in terms of efficacy, dosing frequency, and adverse events.

Main Methods:

  • Single-dose and randomized clinical trials were conducted in patients with CKD undergoing dialysis or with chronic renal insufficiency.
  • Pharmacokinetic parameters, including terminal half-life, were assessed.

Related Experiment Videos

  • Hemoglobin (Hb) levels were monitored to assess efficacy.
  • Adverse events, withdrawals, and immune responses were recorded and compared between treatment groups.

    • Main Results:

    • Darbepoetin alfa demonstrated a significantly longer terminal half-life compared to r-HuEPO after both intravenous and subcutaneous administration.
    • Once-weekly administration of darbepoetin alfa achieved similar hemoglobin increases as more frequent dosing of darbepoetin alfa or r-HuEPO.
    • No significant differences in the frequency of adverse events, withdrawals, or deaths were observed between darbepoetin alfa and r-HuEPO groups.
    • No immune responses to darbepoetin alfa were reported in a large patient cohort.

    Conclusions:

    • Darbepoetin alfa is an effective and well-tolerated treatment for anemia in CKD patients.
    • Its longer half-life allows for less frequent administration compared to r-HuEPO, potentially improving patient convenience.
    • Darbepoetin alfa offers a comparable safety profile to r-HuEPO.